Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Decitabine and venetoclax for AML

Abhishek Maiti • 1 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Quizartinib Venetoclax

Abhishek Maiti, MD, University of Texas MD Anderson Cancer Center, Houston, TX, reports on a Phase II study (NCT03404193) investigating decitabine and venetoclax therapy in patients with untreated or relapsed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abhishek Maiti

2:16
Rationale for 10-day decitabine with venetoclax for high-risk AML
Abhishek Maiti • 1 Jun 2020
2:05
Venetoclax with decitabine for high-risk AML and MDS
Abhishek Maiti • 2 Jun 2020
9:17
Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti • 2 Jun 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals